Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.37 USD

28.37
7,206,909

+0.07 (0.25%)

Updated Nov 1, 2024 11:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

by Zacks Equity Research

Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.

Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns

by Zacks Equity Research

Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.

J&J (JNJ) to Explore Omicron Version of its COVID Vaccine

by Zacks Equity Research

J&J (JNJ) is testing the blood serum from participants of completed and ongoing booster studies for neutralizing activity against the Omicron variant

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

by Zacks Equity Research

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Sanghamitra Saha headshot

ETF Areas to Gain/Lose on Fear of Omicron Strain of Coronavirus

by Sanghamitra Saha

The emergence of a new coronavirus strain, namely Omicron, has caused a massacre on Wall Street on Friday. These ETFs could gain/lose in the coming days if Omicron cases continue to rise.

Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why

by Zacks Equity Research

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

Cyber Monday to Determine Holiday Sales Fate

by Zacks Equity Research

Cyber Monday to Determine Holiday Sales Fate

Mark Vickery headshot

Will Cyber Monday Rescue Holiday Shopping from Omicron Fears?

by Mark Vickery

Pre-market futures this morning are buoyant, indicating market participants may have overreacted to the Friday news.

Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down

by Zacks Equity Research

Merck's (MRK) new data from a phase III study shows its COVID-19 antiviral pill is less effective than previously reported.

4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

by Zacks Equity Research

Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

Wall Street Tumbles on Resurgence of Coronavirus

by Zacks Equity Research

Wall Street Tumbles on Resurgence of Coronavirus.

Mark Vickery headshot

Black Friday Meets "Black Friday:" New Covid Variant Hits Markets

by Mark Vickery

A new Covid strain threatens the global marketplace anew, just as economic conditions around the world were beginning to get their footing following the Delta-variant fallout.

Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11

by Zacks Equity Research

Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids

by Kinjel Shah

FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.

J&J (JNJ) Gets First Full Approval for COVID Jab in Canada

by Zacks Equity Research

Canada grants full approval to J&J's (JNJ) COVID vaccine, making it the first full approval for the vaccine globally.

Pfizer (PFE) COVID Vaccine & Pill Drive Stock Up This Year

by Zacks Equity Research

Pfizer's (PFE) stock is up 38.8% this year so far, riding high on the success of its two-shot vaccine for COVID-19.

Sweta Jaiswal, FRM headshot

Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging updates in the coronavirus vaccine.

FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults

by Zacks Equity Research

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

Stock Market News for Nov 22, 2021

by Zacks Equity Research

Wall Street closed mixed on Friday to end a choppy week.

FDA Gives Authorization to Two COVID-19 Boosters

by Zacks Equity Research

FDA Gives Authorization to Two COVID-19 Boosters

Mark Vickery headshot

FDA Authorizes Covid Boosters; New Fed Chair Soon?

by Mark Vickery

Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."

Merck's (MRK) Keytruda Gets Approval for Certain RCC Patients

by Zacks Equity Research

Merck's (MRK) anti-PD-1 therapy Keytruda gets FDA nod as an adjuvant treatment for patients with renal cell carcinoma at intermediate-high or high risk of recurrence, following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.

by Zacks Equity Research

The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Spin Off Consumer Unit, PFE Eyes EUA for COVID Pill

by Kinjel Shah

J&J (JNJ) decides to split into two companies. Pfizer (PFE) seeks nod for emergency use of COVID antiviral pill. Glaxo's (GSK) and AbbVie's (ABBV) drugs get approvals in new indications.